TECHWIRE 30
(CIX: WRAL30)  1,133.39  up arrow+12.57  (1.12 %)  Updated: 12:38 PM EDT, May 25 2016
(NQ: Apple)  99.17  up arrow+1.27  (1.3 %)  Updated: 12:39 PM EDT, May 25 2016
(NY: Q)  66.86  down arrow-0.06  (-0.09 %)  Updated: 12:38 PM EDT, May 25 2016
(OP: BASFY)  77.81  up arrow+0.33  (0.43 %)  Updated: 12:02 PM EDT, May 25 2016
(NQ: BCRX)  3.30  down arrow-0.05  (-1.49 %)  Updated: 12:38 PM EDT, May 25 2016
(NQ: BDSI)  2.12  up arrow+0.12  (6 %)  Updated: 12:38 PM EDT, May 25 2016
(NQ: CEMP)  17.35  up arrow+0.44  (2.6 %)  Updated: 12:38 PM EDT, May 25 2016
(NQ: Cisco)  28.89  up arrow+0.42  (1.46 %)  Updated: 12:39 PM EDT, May 25 2016
(NQ: CREE)  24.08  up arrow+0.24  (1.01 %)  Updated: 12:38 PM EDT, May 25 2016
(NQ: DARA)  0.88    (0 %)  Updated: 08:10 PM EST, Dec 04 2015
(NY: EMC)  27.82  down arrow-0.06  (-0.2 %)  Updated: 12:39 PM EDT, May 25 2016
(NQ: EXTR)  3.71  down arrow-0.04  (-0.94 %)  Updated: 12:38 PM EDT, May 25 2016
(NQ: Facebook)  117.91  up arrow+0.21  (0.18 %)  Updated: 12:39 PM EDT, May 25 2016
(NY: GSK)  43.13  up arrow+0.42  (0.98 %)  Updated: 12:38 PM EDT, May 25 2016
(NQ: Alphabet)  724.61  up arrow+4.52  (0.63 %)  Updated: 12:38 PM EDT, May 25 2016
(NY: IBM)  151.08  up arrow+2.77  (1.87 %)  Updated: 12:38 PM EDT, May 25 2016

Posts tagged “Talecris”

Updated April 11, 2013

Premium Lock Chimerix goes public, offers more shares; IPO prices shares at $14

Chimerix raises more than $100 million. The RTP firm plans to use IPO proceeds to fund R&D, particularly phase III clinical trials on its lead therapeutic program.

Chimerix drug pipeline as cited in IPO filing. Chimerix drug pipeline as cited in IPO filing.

Updated April 11, 2013

Premium Lock Shares in Grifols, which bought RTP-based Talecris, soar as plasma prices surge

Grifols Talecris Biotherapeutics, once one of the largest life science firms in the Triangle, is no more since its assets were incorporated into Spain-based Grifols as part of a $4 billion merger. But the investment Grifols made in acquiring Talecris two years ago, continues to pay dividends.

Updated April 24, 2012

Premium Lock Talecris acquisition boosts Grifols sales, earnings

Grifols The Spain-based blood plasma firm reports big jump in sales and profits in wake of RTP-based Talecris takeover.

February 1, 2012

Premium Lock Grifols - buyer of RTP-based Talecris - seeking $3.4B

Plasma The Spain-based maker of blood plasma products is seeking to refinance the debt it raised in order to buy its rival Talecris, according to Bloomberg news.

June 8, 2011

Premium Lock New Talecris owner Grifols affirms commitment to expansion

Talecris Spain-based Grifols, the new owner of RTP-based Talecris Biotherapeutics, said Wednesday that the company plans to proceed with expansion of the massive Talecris expansion plant in nearby Clayton.

Updated June 6, 2011

Premium Lock Merger complete, Grifols names board for Talecris integration

Plasma The Spain-based life sciences company, which acquired RTP-based Talecris for more than $3 billion, puts in place a former Baxter executive and a team to oversee integration of the two companies.

Updated June 1, 2011

Premium Lock Talecris, Grifols receive government approval for $4B merger

Talecris The closing could take place as early as Wednesday now that the FTC has formally signed off on the deal, the RTP-based biotherapeutics firm says.

May 24, 2011

Premium Lock Report: Grifols expects to close on Talecris deal in early June

Talecris At a shareholders meeting in Spain on Tuesday, Grifols said in a statement that it expects final regulatory approval for the $4 billion deal in early June, according to Reuters.

April 28, 2011

Premium Lock Talecris tops Street on profit but misses on revenue

Talecris The RTP-based biotherapeutics firm is still awaiting approval of its proposed merger with Spain-based Grifols.

April 11, 2011

Premium Lock Street becomes more optimistic $4.5B Talecris deal will close

Talecris "There is a high level of confidence that they're going to get approval any day," a vice president of merger arbitrage trading and sales at Wall Street Access tells Bloomberg news. "I'm still taken aback as to why this has taken so long."

April 7, 2011

Premium Lock Grifols chairman is confident US will approve Talecris merger

Talecris The Spain-based life sciences firm is awaiting FTC decision on $3.8 billion deal for Triangle-based blood plasma therapeutics producer.

March 4, 2011

Premium Lock Talecris, Grifols push back merger close target date to June 30

Talecris The companies are still seeking US government approval for the deal that would combine two of the world's largest plasma-based therapeutics providers.

February 24, 2011

Premium Lock Talecris matches Wall Street expectations on profit

Talecris The biotherapeutics firm reports a 38-cent per share quarterly profit and says its revenues increased 4.5 percent for the year to $1.6 billion.

February 11, 2011

Premium Lock Grifols targets March 21 as earliest date for Talecris deal closure

Grifols As FTC decision looms, the Spanish life sciences firm pushes back the possible closing of the $4 billion deal to take over RTP-based Talecris.

February 4, 2011

Premium Lock Grifols expects ruling on $4B Talecris deal by March 6

Talecris Reuters news reports that the Spanish company apparently is still talking to US regulators about the buyout of the RTP-based biotherapeutics firm.

January 17, 2011

Premium Lock Talecris sets vote on merger with Grifols

Talecris Shareholders will be asked to approve the multi-billion deal on Feb. 14.

January 13, 2011

Premium Lock Grifols sells $1.1B in bonds for Talecris buyout

Grifols The Spain-based life sciences conglomerate is in the process of acquiring RTP-based Talecris Biotherapeutics. It had hoped to sell the bonds in December.

December 14, 2010

Premium Lock Talecris loses in contract dispute; jury awards $37M

Talecris The RTP-based plasma therapeutics firm and Plasma Centers of America were fighting over a terminated acquisition agreement.

December 1, 2010

Premium Lock Report: Grifols may face delay in financing for Talecris deal

Grifols The Spanish pharmaceutical firm said last week that it had the money lined up for the $3.4 billion deal.

November 25, 2010

Premium Lock Spanish drug firm Grifols says it has $3.4B to buy Talecris

Talecris The RTP-based blood plasma therapeutics firm would become part of the Spanish conglomerate if regulators approve the merger.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith